Compare Annaly Capital Management, Inc. (NLY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Annaly Capital Management, Inc. trades at $18.15 (market cap $13.77B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NLY | ZBH | |
|---|---|---|
Market Cap | $13.77B | $16.95B |
Volume | 21,283,879 | 2,505,240 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $103.98 |
52-Week Low | $17.93 | $79.58 |
Typical Hold Time | 92 Days | 89 Days |
Enterprise Value | $135.80B | $24.02B |
Dividend Yield | 16.42% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.07, up 0.78% today, with a bearish technical signal despite oversold RSI readings. The stock offers a high dividend yield near 15% and trades below book value (P/B 0.91). Recent quarters show consistent EPS beats, with Q3 2026 results pending. The company's portfolio expansion to $107 billion in 2026 supports earnings growth, though cash flow trends show heavy reliance on financing activities.
The outlook balances high income potential against interest rate sensitivity. Analyst consensus is bullish with a $22 price target, but rising debt-to-asset ratios and mortgage rate volatility pose risks. Sustainable dividend coverage remains key for total return prospects amid market uncertainty.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
